{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:31:57Z","timestamp":1793460717336,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Clemastine (CLE), an H1R antagonist widely used for the treatment of allergic rhinitis, has recently been investigated for its positive modulatory effects on P2X7, a receptor for extracellular ATP (eATP) involved in the regulation of inflammation, immune responses, and the composition of the tumor microenvironment (TME). Here, we further examined the effects of CLE on P2X7-mediated responses to clarify the pharmacological significance of P2X7 potentiation. First, in murine and human cells expressing (B16F10 WT and HEK293-hP2X7) or lacking (B16F10 P2X7\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    and HEK293 WT) the P2X7 receptor, we measured intracellular Ca\n                    <jats:sup>2+<\/jats:sup>\n                    influx, ethidium bromide (EB) and daunorubicin (DN) uptake, mitochondrial morphology, and LDH and ATP release following P2X7 agonism or antagonism in the presence of CLE. We found that CLE increased Bz-ATP-induced P2X7-mediated channel opening, pore formation, mitochondrial remodeling, eATP release, and cell death, effects absent in P2X7-null cells and abolished by P2X7 antagonists. As a readout of activation of NLRP3 inflammasome, a known downstream effector of the P2X7 receptor, we also assessed the effect of CLE on IL-1\u03b2 release from peritoneal macrophages from wild-type (WT) or P2X7 knockout (KO) mice, LPS-primed and treated with ATP and\/or CLE. We found that the combined treatment significantly increased IL-1\u03b2 release from P2X7-WT macrophages compared to the two stimuli administered separately. On the whole, our results demonstrate that CLE can effectively positively modulate P2X7 function, suggesting new opportunities for its therapeutic exploitation.\n                  <\/jats:p>","DOI":"10.1007\/s11302-026-10179-x","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:30:45Z","timestamp":1787916645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects on mouse melanoma and immune cells of P2X7 receptor positive allosterism by clemastine"],"prefix":"10.1007","volume":"22","author":[{"given":"Maria Luiza","family":"Thorstenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Falzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio Edith","family":"Garcia-Jacobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia Scussel","family":"Bergamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Tarantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Conversano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pegoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Virgilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Adinolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Lisa","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"7","key":"10179_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002599","volume":"3","author":"P Pellegatti","year":"2008","unstructured":"Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F (2008) Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS ONE 3(7):e2599. https:\/\/doi.org\/10.1371\/journal.pone.0002599","journal-title":"PLoS ONE"},{"issue":"2","key":"10179_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.7150\/thno.66274","volume":"12","author":"V Vultaggio-Poma","year":"2022","unstructured":"Vultaggio-Poma V, Falzoni S, Chiozzi P, Sarti AC, Adinolfi E, Giuliani AL, Sanchez-Melgar A, Boldrini P, Zanoni M, Tesei A, Pinton P, Di Virgilio F (2022) Extracellular ATP is increased by release of ATP-loaded microparticles triggered by nutrient deprivation. Theranostics 12(2):859\u2013874. https:\/\/doi.org\/10.7150\/thno.66274","journal-title":"Theranostics"},{"key":"10179_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108700","volume":"262","author":"F Di Virgilio","year":"2024","unstructured":"Di Virgilio F, Vultaggio-Poma V, Tarantini M, Giuliani AL (2024) Overview of the role of purinergic signaling and insights into its role in cancer therapy. Pharmacol Ther 262:108700. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108700","journal-title":"Pharmacol Ther"},{"key":"10179_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/bs.mcb.2025.02.014","volume":"199","author":"M Tarantini","year":"2025","unstructured":"Tarantini M, Vultaggio-Poma V, Falzoni S, Adinolfi E, Giuliani AL, Di Virgilio F (2025) In-vivo measurement of the extracellular ATP concentration by bio-luminescence: the pmeLUC probe. Methods Cell Biol 199:53\u201366. https:\/\/doi.org\/10.1016\/bs.mcb.2025.02.014","journal-title":"Methods Cell Biol"},{"issue":"10","key":"10179_CR5","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41568-018-0037-0","volume":"18","author":"F Di Virgilio","year":"2018","unstructured":"Di Virgilio F, Sarti AC, Falzoni S, De Marchi E, Adinolfi E (2018) Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat Rev Cancer 18(10):601\u2013618. https:\/\/doi.org\/10.1038\/s41568-018-0037-0","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10179_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0031-6997(24)01373-5","volume":"50","author":"V Ralevic","year":"1998","unstructured":"Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50(3):413\u2013492","journal-title":"Pharmacol Rev"},{"issue":"4","key":"10179_CR7","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1152\/physrev.00015.2002","volume":"82","author":"RA North","year":"2002","unstructured":"North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82(4):1013\u20131067. https:\/\/doi.org\/10.1152\/physrev.00015.2002","journal-title":"Physiol Rev"},{"key":"10179_CR8","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2015.0427","author":"RA North","year":"2016","unstructured":"North RA (2016) P2X receptors. Philos Trans R Soc Lond B Biol Sci. https:\/\/doi.org\/10.1098\/rstb.2015.0427","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"5","key":"10179_CR9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.tcb.2018.01.005","volume":"28","author":"F Di Virgilio","year":"2018","unstructured":"Di Virgilio F, Schmalzing G, Markwardt F (2018) The elusive P2X7 macropore. Trends Cell Biol 28(5):392\u2013404. https:\/\/doi.org\/10.1016\/j.tcb.2018.01.005","journal-title":"Trends Cell Biol"},{"issue":"1","key":"10179_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","volume":"47","author":"F Di Virgilio","year":"2017","unstructured":"Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S (2017) The P2X7 receptor in infection and inflammation. Immunity 47(1):15\u201331. https:\/\/doi.org\/10.1016\/j.immuni.2017.06.020","journal-title":"Immunity"},{"key":"10179_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114385","volume":"187","author":"P Pelegrin","year":"2021","unstructured":"Pelegrin P (2021) P2X7 receptor and the NLRP3 inflammasome: partners in crime. Biochem Pharmacol 187:114385. https:\/\/doi.org\/10.1016\/j.bcp.2020.114385","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10179_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12029-022-00805-3","volume":"54","author":"M Ghanawat","year":"2023","unstructured":"Ghanawat M, Arjmand B, Rahim F (2023) The pro-tumor and anti-tumor effects of NLRP3 inflammasome as a new therapeutic option for colon cancer: a meta-analysis of pre-clinical studies. J Gastrointest Cancer 54(1):227\u2013236. https:\/\/doi.org\/10.1007\/s12029-022-00805-3","journal-title":"J Gastrointest Cancer"},{"key":"10179_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108545","volume":"251","author":"IW Tengesdal","year":"2023","unstructured":"Tengesdal IW, Dinarello CA, Marchetti C (2023) NLRP3 and cancer: pathogenesis and therapeutic opportunities. Pharmacol Ther 251:108545. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108545","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10179_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11302-020-09735-w","volume":"17","author":"F Di Virgilio","year":"2021","unstructured":"Di Virgilio F (2021) P2X7 is a cytotoxic receptor....maybe not: implications for cancer. Purinergic Signal 17(1):55\u201361. https:\/\/doi.org\/10.1007\/s11302-020-09735-w","journal-title":"Purinergic Signal"},{"key":"10179_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.645605","volume":"9","author":"E De Marchi","year":"2021","unstructured":"De Marchi E, Pegoraro A, Adinolfi E (2021) P2X7 receptor in hematological malignancies. Front Cell Dev Biol 9:645605. https:\/\/doi.org\/10.3389\/fcell.2021.645605","journal-title":"Front Cell Dev Biol"},{"key":"10179_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25126673","author":"A Pegoraro","year":"2024","unstructured":"Pegoraro A, Grignolo M, Ruo L, Ricci L, Adinolfi E (2024) P2X7 variants in pathophysiology. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25126673","journal-title":"Int J Mol Sci"},{"key":"10179_CR17","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3389\/fphar.2020.00627","volume":"11","author":"L Stokes","year":"2020","unstructured":"Stokes L, Bidula S, Bibic L, Allum E (2020) To inhibit or enhance? Is there a benefit to positive allosteric modulation of P2X receptors? Front Pharmacol 11:627. https:\/\/doi.org\/10.3389\/fphar.2020.00627","journal-title":"Front Pharmacol"},{"issue":"4","key":"10179_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s11302-021-09811-9","volume":"17","author":"S Janho Dit Hreich","year":"2021","unstructured":"Janho Dit Hreich S, Benzaquen J, Hofman P, Vouret-Craviari V (2021) To inhibit or to boost the ATP\/P2RX7 pathway to fight cancer-that is the question. Purinergic Signal 17(4):619\u2013631. https:\/\/doi.org\/10.1007\/s11302-021-09811-9","journal-title":"Purinergic Signal"},{"key":"10179_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119235","author":"S Janho Dit Hreich","year":"2023","unstructured":"Janho Dit Hreich S, Hofman P, Vouret-Craviari V (2023) The role of IL-18 in P2RX7-mediated antitumor immunity. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24119235","journal-title":"Int J Mol Sci"},{"key":"10179_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fphar.2018.00039","volume":"9","author":"F Di Virgilio","year":"2018","unstructured":"Di Virgilio F, Giuliani AL, Vultaggio-Poma V, Falzoni S, Sarti AC (2018) Non-nucleotide agonists triggering P2X7 receptor activation and pore formation. Front Pharmacol 9:39. https:\/\/doi.org\/10.3389\/fphar.2018.00039","journal-title":"Front Pharmacol"},{"issue":"1","key":"10179_CR21","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/s41467-021-20912-2","volume":"12","author":"L Douguet","year":"2021","unstructured":"Douguet L, JanhoDitHreich S, Benzaquen J, Seguin L, Juhel T, Dezitter X, Duranton C, Ryffel B, Kanellopoulos J, Delarasse C, Renault N, Furman C, Homerin G, Feral C, Cherfils-Vicini J, Millet R, Adriouch S, Ghinet A, Hofman P, Vouret-Craviari V (2021) A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy. Nat Commun 12(1):653. https:\/\/doi.org\/10.1038\/s41467-021-20912-2","journal-title":"Nat Commun"},{"issue":"7","key":"10179_CR22","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.4049\/jimmunol.0803612","volume":"182","author":"JM Sanz","year":"2009","unstructured":"Sanz JM, Chiozzi P, Ferrari D, Colaianna M, Idzko M, Falzoni S, Fellin R, Trabace L, Di Virgilio F (2009) Activation of microglia by amyloid beta requires P2X7 receptor expression. J Immunol 182(7):4378\u20134385. https:\/\/doi.org\/10.4049\/jimmunol.0803612","journal-title":"J Immunol"},{"issue":"45","key":"10179_CR23","doi-asserted-by":"publisher","first-page":"30471","DOI":"10.1074\/jbc.M802185200","volume":"283","author":"L Tomasinsig","year":"2008","unstructured":"Tomasinsig L, Pizzirani C, Skerlavaj B, Pellegatti P, Gulinelli S, Tossi A, Di Virgilio F, Zanetti M (2008) The human cathelicidin LL-37 modulates the activities of the P2X7 receptor in a structure-dependent manner. J Biol Chem 283(45):30471\u201330481. https:\/\/doi.org\/10.1074\/jbc.M802185200","journal-title":"J Biol Chem"},{"issue":"13","key":"10179_CR24","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1111\/bph.13123","volume":"172","author":"RM Helliwell","year":"2015","unstructured":"Helliwell RM, ShioukHuey CO, Dhuna K, Molero JC, Ye JM, Xue CC, Stokes L (2015) Selected ginsenosides of the protopanaxdiol series are novel positive allosteric modulators of P2X7 receptors. Br J Pharmacol 172(13):3326\u20133340. https:\/\/doi.org\/10.1111\/bph.13123","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10179_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11302-023-09935-0","volume":"20","author":"K Dhuna","year":"2024","unstructured":"Dhuna K, Helliwell R, De Luca SN, Spencer SJ, Stokes L (2024) Ginsenosides enhance P2X7-dependent cytokine secretion from LPS-primed rodent macrophages. Purinergic Signal 20(1):65\u201371. https:\/\/doi.org\/10.1007\/s11302-023-09935-0","journal-title":"Purinergic Signal"},{"issue":"2\u20133","key":"10179_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0014-2999(98)00482-8","volume":"355","author":"JM Sanz","year":"1998","unstructured":"Sanz JM, Chiozzi P, Di Virgilio F (1998) Tenidap enhances P2Z\/P2X7 receptor signalling in macrophages. Eur J Pharmacol 355(2\u20133):235\u2013244","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"10179_CR27","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.4049\/jimmunol.173.7.4652","volume":"173","author":"D Ferrari","year":"2004","unstructured":"Ferrari D, Pizzirani C, Adinolfi E, Forchap S, Sitta B, Turchet L, Falzoni S, Minelli M, Baricordi R, Di Virgilio F (2004) The antibiotic polymyxin B modulates P2X7 receptor function. J Immunol 173(7):4652\u20134660","journal-title":"J Immunol"},{"issue":"4","key":"10179_CR28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/sj.bjp.0706994","volume":"150","author":"D Ferrari","year":"2007","unstructured":"Ferrari D, Pizzirani C, Gulinelli S, Callegari G, Chiozzi P, Idzko M, Panther E, Di Virgilio F (2007) Modulation of P2X7 receptor functions by polymyxin B: crucial role of the hydrophobic tail of the antibiotic molecule. Br J Pharmacol 150(4):445\u2013454. https:\/\/doi.org\/10.1038\/sj.bjp.0706994","journal-title":"Br J Pharmacol"},{"issue":"13","key":"10179_CR29","doi-asserted-by":"publisher","first-page":"11067","DOI":"10.1074\/jbc.M110.198879","volume":"286","author":"W Norenberg","year":"2011","unstructured":"Norenberg W, Hempel C, Urban N, Sobottka H, Illes P, Schaefer M (2011) Clemastine potentiates the human P2X7 receptor by sensitizing it to lower ATP concentrations. J Biol Chem 286(13):11067\u201311081. https:\/\/doi.org\/10.1074\/jbc.M110.198879","journal-title":"J Biol Chem"},{"issue":"8","key":"10179_CR30","doi-asserted-by":"publisher","first-page":"9609","DOI":"10.1007\/s00210-025-03978-3","volume":"398","author":"S Soni","year":"2025","unstructured":"Soni S, Kaur G (2025) Emerging therapeutic application of clemastine: a review of recent patents updates. Naunyn-Schmiedebergs Arch Pharmacol 398(8):9609\u20139622. https:\/\/doi.org\/10.1007\/s00210-025-03978-3","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"7","key":"10179_CR31","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1091\/mbc.02-04-0061","volume":"14","author":"A Morelli","year":"2003","unstructured":"Morelli A, Chiozzi P, Chiesa A, Ferrari D, Sanz JM, Falzoni S, Pinton P, Rizzuto R, Olson MF, Di Virgilio F (2003) Extracellular ATP causes ROCK I-dependent bleb formation in P2X7-transfected HEK293 cells. Mol Biol Cell 14(7):2655\u20132664. https:\/\/doi.org\/10.1091\/mbc.02-04-0061","journal-title":"Mol Biol Cell"},{"issue":"2","key":"10179_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbabio.2023.149027","volume":"1865","author":"S Desai","year":"2024","unstructured":"Desai S, Grefte S, van de Westerlo E, Lauwen S, Paters A, Prehn JHM, Gan Z, Keijer J, Adjobo-Hermans MJW, Koopman WJH (2024) Performance of TMRM and Mitotrackers in mitochondrial morphofunctional analysis of primary human skin fibroblasts. Biochim Biophys Acta Bioenerg 1865(2):149027. https:\/\/doi.org\/10.1016\/j.bbabio.2023.149027","journal-title":"Biochim Biophys Acta Bioenerg"},{"key":"10179_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/srep35065","volume":"6","author":"R Juge","year":"2016","unstructured":"Juge R, Breugnot J, Da Silva C, Bordes S, Closs B, Aouacheria A (2016) Quantification and characterization of UVB-induced mitochondrial fragmentation in normal primary human keratinocytes. Sci Rep 6:35065. https:\/\/doi.org\/10.1038\/srep35065","journal-title":"Sci Rep"},{"issue":"8","key":"10179_CR34","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/nprot.2017.052","volume":"12","author":"G Morciano","year":"2017","unstructured":"Morciano G, Sarti AC, Marchi S, Missiroli S, Falzoni S, Raffaghello L, Pistoia V, Giorgi C, Di Virgilio F, Pinton P (2017) Use of luciferase probes to measure ATP in living cells and animals. Nat Protoc 12(8):1542\u20131562. https:\/\/doi.org\/10.1038\/nprot.2017.052","journal-title":"Nat Protoc"},{"issue":"10","key":"10179_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03058-9","volume":"11","author":"A Pegoraro","year":"2020","unstructured":"Pegoraro A, Orioli E, De Marchi E, Salvestrini V, Milani A, Di Virgilio F, Curti A, Adinolfi E (2020) Differential sensitivity of acute myeloid leukemia cells to daunorubicin depends on P2X7A versus P2X7B receptor expression. Cell Death Dis 11(10):876. https:\/\/doi.org\/10.1038\/s41419-020-03058-9","journal-title":"Cell Death Dis"},{"issue":"40","key":"10179_CR36","doi-asserted-by":"publisher","first-page":"33968","DOI":"10.1074\/jbc.M502705200","volume":"280","author":"AB Mackenzie","year":"2005","unstructured":"Mackenzie AB, Young MT, Adinolfi E, Surprenant A (2005) Pseudoapoptosis induced by brief activation of ATP-gated P2X7 receptors. J Biol Chem 280(40):33968\u201333976. https:\/\/doi.org\/10.1074\/jbc.M502705200","journal-title":"J Biol Chem"},{"issue":"2","key":"10179_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/function\/zqab005","volume":"2","author":"AC Sarti","year":"2021","unstructured":"Sarti AC, Vultaggio-Poma V, Falzoni S, Missiroli S, Giuliani AL, Boldrini P, Bonora M, Faita F, Di Lascio N, Kusmic C, Solini A, Novello S, Morari M, Rossato M, Wieckowski MR, Giorgi C, Pinton P, Di Virgilio F (2021) Mitochondrial P2X7 receptor localization modulates energy metabolism enhancing physical performance. Function (Oxf) 2(2):zqab005. https:\/\/doi.org\/10.1093\/function\/zqab005","journal-title":"Function (Oxf)"},{"issue":"2","key":"10179_CR38","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41418-022-01095-9","volume":"30","author":"S Missiroli","year":"2023","unstructured":"Missiroli S, Perrone M, Gafa R, Nicoli F, Bonora M, Morciano G, Boncompagni C, Marchi S, Lebiedzinska-Arciszewska M, Vezzani B, Lanza G, Kricek F, Borghi A, Fiorica F, Ito K, Wieckowski MR, Di Virgilio F, Abelli L, Pinton P, Giorgi C (2023) PML at mitochondria-associated membranes governs a trimeric complex with NLRP3 and P2X7R that modulates the tumor immune microenvironment. Cell Death Differ 30(2):429\u2013441. https:\/\/doi.org\/10.1038\/s41418-022-01095-9","journal-title":"Cell Death Differ"},{"issue":"5","key":"10179_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2022.119237","volume":"1869","author":"V Vultaggio-Poma","year":"2022","unstructured":"Vultaggio-Poma V, Falzoni S, Salvi G, Giuliani AL, Di Virgilio F (2022) Signalling by extracellular nucleotides in health and disease. Biochim Biophys Acta Mol Cell Res 1869(5):119237. https:\/\/doi.org\/10.1016\/j.bbamcr.2022.119237","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10179_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2025.101997","volume":"80","author":"S Sepehri-Manesh","year":"2025","unstructured":"Sepehri-Manesh S, Debeaud M, Vouret-Craviari V (2025) Unlocking IL-18: a hidden key in cancer immunity. Semin Immunol 80:101997. https:\/\/doi.org\/10.1016\/j.smim.2025.101997","journal-title":"Semin Immunol"},{"key":"10179_CR41","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.39123","author":"MA Matty","year":"2019","unstructured":"Matty MA, Knudsen DR, Walton EM, Beerman RW, Cronan MR, Pyle CJ, Hernandez RE, Tobin DM (2019) Potentiation of P2RX7 as a host-directed strategy for control of mycobacterial infection. Elife. https:\/\/doi.org\/10.7554\/eLife.39123","journal-title":"Elife"},{"key":"10179_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.966404","volume":"12","author":"VF Arnaud-Sampaio","year":"2022","unstructured":"Arnaud-Sampaio VF, Bento CA, Glaser T, Adinolfi E, Ulrich H, Lameu C (2022) P2X7 receptor isoform B is a key drug resistance mediator for neuroblastoma. Front Oncol 12:966404. https:\/\/doi.org\/10.3389\/fonc.2022.966404","journal-title":"Front Oncol"},{"issue":"12","key":"10179_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04378-0","volume":"12","author":"A Pegoraro","year":"2021","unstructured":"Pegoraro A, De Marchi E, Ferracin M, Orioli E, Zanoni M, Bassi C, Tesei A, Capece M, Dika E, Negrini M, Di Virgilio F, Adinolfi E (2021) P2X7 promotes metastatic spreading and triggers release of miRNA-containing exosomes and microvesicles from melanoma cells. Cell Death Dis 12(12):1088. https:\/\/doi.org\/10.1038\/s41419-021-04378-0","journal-title":"Cell Death Dis"},{"key":"10179_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2021.100398","volume":"31","author":"L Tattersall","year":"2021","unstructured":"Tattersall L, Shah KM, Lath DL, Singh A, Down JM, De Marchi E, Williamson A, Di Virgilio F, Heymann D, Adinolfi E, Fraser WD, Green D, Lawson MA, Gartland A (2021) The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties. J Bone Oncol 31:100398. https:\/\/doi.org\/10.1016\/j.jbo.2021.100398","journal-title":"J Bone Oncol"},{"issue":"1","key":"10179_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07897-2","volume":"16","author":"A Pegoraro","year":"2025","unstructured":"Pegoraro A, De Marchi E, Ruo L, Zanoni M, Chioccioli S, Caderni G, Alfieri L, Grignolo M, Ulivi P, Passardi A, Gallo G, Antonioli L, Di Virgilio F, Adinolfi E (2025) P2X7 a new therapeutic target to block vesicle-dependent metastasis in colon carcinoma: role of the A2A\/CD39\/CD73 axis. Cell Death Dis 16(1):587. https:\/\/doi.org\/10.1038\/s41419-025-07897-2","journal-title":"Cell Death Dis"},{"issue":"11","key":"10179_CR46","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.tibs.2025.09.001","volume":"50","author":"L Hohorst","year":"2025","unstructured":"Hohorst L, Ros U, Garcia-Saez AJ (2025) Mitochondrial dynamics and pore formation in regulated cell death pathways. Trends Biochem Sci 50(11):1001\u20131014. https:\/\/doi.org\/10.1016\/j.tibs.2025.09.001","journal-title":"Trends Biochem Sci"},{"issue":"7","key":"10179_CR47","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1091\/mbc.E04-11-1025","volume":"16","author":"E Adinolfi","year":"2005","unstructured":"Adinolfi E, Callegari MG, Ferrari D, Bolognesi C, Minelli M, Wieckowski MR, Pinton P, Rizzuto R, Di Virgilio F (2005) Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell 16(7):3260\u20133272. https:\/\/doi.org\/10.1091\/mbc.E04-11-1025","journal-title":"Mol Biol Cell"},{"issue":"1","key":"10179_CR48","doi-asserted-by":"publisher","first-page":"6475","DOI":"10.1038\/s41598-019-42931-2","volume":"9","author":"P Chiozzi","year":"2019","unstructured":"Chiozzi P, Sarti AC, Sanz JM, Giuliani AL, Adinolfi E, Vultaggio-Poma V, Falzoni S, Di Virgilio F (2019) Amyloid beta-dependent mitochondrial toxicity in mouse microglia requires P2X7 receptor expression and is prevented by nimodipine. Sci Rep 9(1):6475. https:\/\/doi.org\/10.1038\/s41598-019-42931-2","journal-title":"Sci Rep"},{"issue":"9","key":"10179_CR49","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1096\/fj.09-153601","volume":"24","author":"E Adinolfi","year":"2010","unstructured":"Adinolfi E, Cirillo M, Woltersdorf R, Falzoni S, Chiozzi P, Pellegatti P, Callegari MG, Sandona D, Markwardt F, Schmalzing G, Di Virgilio F (2010) Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor. FASEB J 24(9):3393\u20133404. https:\/\/doi.org\/10.1096\/fj.09-153601","journal-title":"FASEB J"},{"issue":"6","key":"10179_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2024.100713","volume":"47","author":"ML Thorstenberg","year":"2024","unstructured":"Thorstenberg ML, Martins MDA, Oliveira NF, Monteiro M, Santos GRC, Pereira HMG, Savio LEB, Coutinho-Silva R, Silva CLM (2024) Altered purinergic P2X7 and A(2B) receptors signaling limits macrophage-mediated host defense in schistosomiasis. Biomed J 47(6):100713. https:\/\/doi.org\/10.1016\/j.bj.2024.100713","journal-title":"Biomed J"},{"key":"10179_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1446486","volume":"15","author":"S Wang","year":"2024","unstructured":"Wang S, He H, Qu L, Shen Q, Dai Y (2024) Dual roles of inflammatory programmed cell death in cancer: insights into pyroptosis and necroptosis. Front Pharmacol 15:1446486. https:\/\/doi.org\/10.3389\/fphar.2024.1446486","journal-title":"Front Pharmacol"},{"key":"10179_CR52","doi-asserted-by":"publisher","DOI":"10.1172\/JCI183941","author":"J Kocot","year":"2025","unstructured":"Kocot J, Kosa P, Ashida S, Pirjanian NA, Goldbach-Mansky R, Peterson K, Fossati V, Holland SM, Bielekova B (2025) Clemastine fumarate accelerates accumulation of disability in progressive multiple sclerosis by enhancing pyroptosis. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI183941","journal-title":"J Clin Invest"},{"key":"10179_CR53","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.coph.2019.02.012","volume":"47","author":"E Adinolfi","year":"2019","unstructured":"Adinolfi E, De Marchi E, Orioli E, Pegoraro A, Di Virgilio F (2019) Role of the P2X7 receptor in tumor-associated inflammation. Curr Opin Pharmacol 47:59\u201364. https:\/\/doi.org\/10.1016\/j.coph.2019.02.012","journal-title":"Curr Opin Pharmacol"},{"key":"10179_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.694831","volume":"9","author":"F Grassi","year":"2021","unstructured":"Grassi F, De Ponte Conti B (2021) The P2X7 receptor in tumor immunity. Front Cell Dev Biol 9:694831. https:\/\/doi.org\/10.3389\/fcell.2021.694831","journal-title":"Front Cell Dev Biol"},{"key":"10179_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.dci.2023.105060","volume":"149","author":"D Angosto-Bazarra","year":"2023","unstructured":"Angosto-Bazarra D, Guijarro A, Pelegrin P (2023) Evolution of the gasdermin family and pyroptosis. Dev Comp Immunol 149:105060. https:\/\/doi.org\/10.1016\/j.dci.2023.105060","journal-title":"Dev Comp Immunol"},{"issue":"2","key":"10179_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115233","volume":"44","author":"J Schachter","year":"2025","unstructured":"Schachter J, Guijarro A, Angosto-Bazarra D, Pinilla M, Hurtado-Navarro L, Meunier E, Perez-Oliva AB, Schwarzbaum PJ, Pelegrin P (2025) Gasdermin D mediates a fast transient release of ATP after NLRP3 inflammasome activation before ninjurin 1-induced lytic cell death. Cell Rep 44(2):115233. https:\/\/doi.org\/10.1016\/j.celrep.2025.115233","journal-title":"Cell Rep"},{"issue":"9","key":"10179_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0332212","volume":"20","author":"M Drill","year":"2025","unstructured":"Drill M, Kan LK, Sequeira RP, Jayakrishnan PC, Hunn M, Jones NC, O\u2019Brien TJ, Monif M (2025) Purinergic P2X receptor 7 (P2X7R) inhibition induced cytotoxicity in glioblastoma. PLoS ONE 20(9):e0332212. https:\/\/doi.org\/10.1371\/journal.pone.0332212","journal-title":"PLoS ONE"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10179-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-026-10179-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10179-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:06:28Z","timestamp":1793459188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-026-10179-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10179"],"URL":"https:\/\/doi.org\/10.1007\/s11302-026-10179-x","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The late FDV was a member of the Scientific Advisory Board of Biosceptre Ltd. (UK), and a consultant at Breye Therapeutics (Denmark) and at Crosslink Therapeutics Inc (USA). All other authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.\u00a0Animal procedures were carried out under authorization of the Italian Ministry of Health (n.\u00a0264\/2021-PR).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"66"}}